Por favor, use este identificador para citar o enlazar este ítem:
https://www.arca.fiocruz.br/handle/icict/34493
Tipo
ArtículoDerechos de autor
Acceso restringido
Fecha del embargo
2100-01-01
Colecciones
- ENSP - Artigos de Periódicos [2347]
- ICICT - Artigos de Periódicos [1382]
- MG - IRR - Artigos de Periódicos [4171]
Metadatos
Mostrar el registro completo del ítem
ESSENTIAL MEDICINES LIST IMPLEMENTATION DYNAMICS: A CASE STUDY USING BRAZILIAN FEDERAL MEDICINES EXPENDITURES
Autor
Afiliación
Universidade Federal do Rio de Janeiro. Faculdade de Farmácia. Rio de Janeiro, Niteroi, RJ, Brazil / Collaboration for Outcomes Research and Evaluation. Faculty of Pharmaceutical Sciences.University of British Columbia. Vancouver, BC, Canada.
Collaboration for Outcomes Research and Evaluation. Faculty of Pharmaceutical Sciences.University of British Columbia. Vancouver, BC, Canada / Centre for Health Evaluation and Outcome Sciences. Providence Health Care Research Institute. Vancouver, BC, Canada.
Fundação Oswaldo Cruz. Instituto René Rachou. Belo Horizonte, MG, Brasil / Department of Medicine. Clinical Epidemiology. Karolinska Institutet. Stockholm, Sweden.
Fundação Oswaldo Cruz. Instituto de Comunicação e Informação Científica e Tecnológica em Saúde. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Escola Nacional de Saúde Pública Sergio Arouca. Rio de Janeiro, RJ, Brasil.
Collaboration for Outcomes Research and Evaluation. Faculty of Pharmaceutical Sciences.University of British Columbia. Vancouver, BC, Canada / Centre for Health Evaluation and Outcome Sciences. Providence Health Care Research Institute. Vancouver, BC, Canada.
Fundação Oswaldo Cruz. Instituto René Rachou. Belo Horizonte, MG, Brasil / Department of Medicine. Clinical Epidemiology. Karolinska Institutet. Stockholm, Sweden.
Fundação Oswaldo Cruz. Instituto de Comunicação e Informação Científica e Tecnológica em Saúde. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Escola Nacional de Saúde Pública Sergio Arouca. Rio de Janeiro, RJ, Brasil.
Resumen en ingles
The aim was to analyse the implementation dynamics of the essential medicines list (EML). We used the government expenditures on medicines and Brazil as a case study. Drug purchases were considered as a proxy for utilization. The essential medicines (EMs) expenditures were followed over time by Brazilian National EMLs life-time and defined by broad therapeutic categories and by specific medicines. Brazil increased the number of the medicines during the last four editions of Brazilian National EMLs and the federal government expenditures on them. The EML implementation dynamics changed the distribution of expenditures on EMs. We identified a common set of 404 EMs present in all four editions of the Brazilian National EMLs. There was a proportional decrease in expenditures on anti-infectives for systemic use, blood and blood-forming organs and alimentary tract and metabolism, and increase in expenditures on antineoplastic and immunomodulating agents. The expenditures distribution per specific medicines revealed that a small set of EMs was responsible for 50% or more of expenditures considering Brazilian National EML life-time for all four periods. The increase in expenditures on EMs in Brazil was a consequence of the newer medicines incorporated over time in the Brazilian National EMLs. The use of the medicines expenditures as a source of data and the definition of an EML life-time permitted follow-up of the implementation dynamics of different versions of the Brazilian National EMLs. Our results have implications for policymakers and stakeholders to gain a better understanding of the role EMLs play in health system sustainability and in the provision of the most beneficial heath care.
Compartir